BSEBoard Meeting31 Oct 2026 · 31 Oct 2026, 02:15 pm

Approved the Un-Audited Standalone Financial Results of the company for the 2nd Quarter ended on 30th September 2026 along with the Limited Review Report and Secretary and Compliance Officer (Key Managerial Personnel) of the Company and Resignation of Company secretary and Compliance Officer vide letter dated 31-10-2026

Hindustan Bio Sciences Ltd · 532041

✦ AI SummaryResults

Hindustan Bio Sciences Ltd has approved its un-audited standalone financial results for the 2nd quarter ended on 30th September 2026, along with a limited review report. The company also announced the resignation of its Company Secretary and Compliance Officer, Mr. Shailendra Vyas, due to his decision to pursue an alternative career opportunity.

Analysis Scores

Earnings Impact5/10
Growth Catalyst2/10
Governance Concern3/10
Regulatory Risk1/10
Balance Sheet Risk4/10
Liquidity Impact6/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Hindustan Bio Sciences Ltd - 532041 - Board Meeting Outcome for Outcome Of Board Meeting Held On 31-10-2026.

Attachments (1)

📄

00e9af3e-ae0e-4c96-a9e0-61b658653c88.pdf

pdf

Download →
View document text
Hindustan BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, ’ Mumbai - 400 001. Scrip Code: 532041 Dear Sir/Madam, Sub: Outcome of Board Meeting held on Saturday, October 31, 2026 as required under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 [“SEBI(LODRY), 2015"] Pursuant to Regulation 30 and other applicable Regulations of SEBI (LODR), 2015, the Board of Directors of the Company in its meeting held today i.e., on October 31, 2026: : 1. Approved the Un-Audited Standalone Financial Results of the company for the 2nd Quarter ended on 30th September 2026 along with the Limited Review Report. 2. Resignation of Company secretary and Compliance Officer Took note of and accepted the resignation of Mr. Shailendra Vyas, Company Secretary and Compliance Officer (Key Managerial Personnel) of the Company, tendered vide his resignation letter dated 31st October, 2026, with effect from the closing hours of 31st October, 2026, due to his decision to pursue an alternative career opportunity outside the Organisation. The details required under Regulation 30 of SEBI (LODR) Regulations, 2015 read with SEBI Master Circular dated November 11, 2024 are enclosed as Annexure A, and a copy of the resignation letter is enclosed as Annexure B. The meeting commenced at 01:00 P.M. and concluded at 02:00 P.M. This is for your information and records. Thanking You, ) For Hindustan Bib Scj J VR Mohan Raju Managing Director DIN: 00060800 +91 40 23555161/ 23555181 HINDUSTAN BIOSCIENCES LTD. pharma.hindustanbio@gmail.com #31, Sagar Society, Road No. 2, www.hindustan.bio Banijara Hills, Hyderabad - 500 034, INDIA. CIN : L26942TG1991PLC0O13564 Plot No.31, SagarH SI oN ciD eU tS y,T A RN o aB dI O No S .2C ,I E BaN nC jE aS ra L HI iM llI sT , E HD y derabad 500 034 STATEMENT OF UN AUDITED RESULTS FOR THE QP Uh Ao Rn Te E N Ro. A2 N35 D5 5 H1 A6 L1 F, F Ya Ex A 4 R0 2 E0 N51 D7 E Q1 D u a 3 r0 teT rH eS nE dP eT dE MBER,2026 Half yoa( rR s on. d oI dn __ _I |a khs) Year onded NE oR . Particulars (3 U0 na0 u9 d2 it0 e2 d6 )| | (3 U0 n. a0 u6 d. i2 t0 e2 d6 ) ] 3 (0 U. n0 a9 u. di2 t0 e2 d5 ]] (3 u0 n. a0 u9 d. i2 t0 e2 d6 ) | (3 u0 n. a0 u9 d. i2 t0 e2 d5 ) | 3 (1 A. u0 d3 i. t2 e0 d2 )6 1 [ I ( (a bn ) )c R Oo e tm hve ee f rnr u Io e nm f oO r mp o ee .mr a ot pi eo rn ats i ons 8 82 522 .8 01 3 0 0. .0 00 -0 ) 0 08 8. 6 8 82 522 .81 03 3 32 2 41 4 39 7 773 3. 771 0 Total Revenue (1) 2| Expenses - - - - - - (a) cost of material consumed 4643 0.00] - 48.13 21.19 44.90] ( ( b ¢) ) P Cu hr ac nh ga es se s i no f I nS vt eo nc tk o r- iI en s- t or fa d fe i nished goods,Stock - - - - - - - In-Trade and Work-in-Progress 572 5.72] 496 145 938 19.35] ( ( {d o 7) ) SFE eim lnp la il n no gcy e Ee C xe o B s ee t nn s se f ei st Expenses 0 0. 10 -37 0 00. . .0 0 00 1 0] 0 0. 30 - 91 0 0. 10 -47 0 0 0. .40 358 9 0 0 1. . .1 0 91 0 9} ) ( (h) D Oe tp hr ee rc i Ea xt pi eo nn ea sn .d amortisation Expenses 541 .. 09 05 115 .. 25 96 | 61 73 15 657 ..5 31 37 8. .6 87 81 16 .. 62 49 ] 3 4| | T P Eo r xt o ca f el i p t tE i i(x oLp o ne s an s l)s ie b ts e ef m( so2 .r) e Exceptionald Extraordinary items and tax (1-2) 3 31 1, .0 - 04 4 ( (1 11 1. .2 29 9) )-] ] ( 5 (5. :8 - 85 5) ) 1 19 9. 77 - 4 4 { (4 4. .4 4-5 5) )] (( 77. .9 93 3) - ) ] 5 | Profit/(Loss) before tax(3 -4) 6 | T (aa )x E urx rp ee nn ts Te as - -- - - - - - - - { { P P Tb b r r a) ) o o xf fp D i ir e Et te f xK /v e p(Li r L eoro o nseu sd s ss s ) e)TT aa f ofo fx x rr e o ts m ih se d i op s ne c tr o ii no ntd ui enf dur eo od pm oc rpo aen trt iai otn niu soi nn sg operations(5-6) 31.0- -- 4 (11.29) -0 - -| | (5- 8 - -- 5 197. - - 4 (a.4- - - 5 ) (( 70 ..0 83 9) - - -) ] 10 | Profit iLoss from Discontinued operations after tax(8-9) 31.04 (11.29) (5.85)] 19.74 (4.45) (7.89)] 1 11 2 | | P Or to hf ei rt / C(L oo ms ps r) ef ho er nt sh ie vp ee r Il no cd o(7 m+ e1 0) - - - - - - A (1) tems that will not be reclassified to profit or loss B ( ( (2 1 2)) )c tI ll i on ta n c es pcs m ro i o osm ff m e iti e te ht d a t oa t a rx t x wor li e rl opl elr sa lo sbt af i i tetn i ng ro g ert c to ll o ai o s it s s tse i em f ms i se t d h t t ha aot t w pi wrl iol lf lin t bo o et r b r l ee o c s lr se a- s sified 31.- - - 0- 4 (11.29- - - )- ] (5- - - 8- 9 19.- - 7- - 4 (4.- - - - 4 5) (7.89- - - - ) | 13 | T (o ct oa ml p rC io sm ip nr ge Ph re on fis ti (v Le o I ssn )c o am ne d f oo tr h eth re c ope mr pi ro ed h ( e1 n1 s+ i1 v2 e) incorme for the period 205.02 205.02] 205.02 206.02 205.02 205.02f 1 154 || RPa ei sd e u rp v eE sq u ei xt cy l uG da ip ni gt a Rl e( vF aa lc ue a v ta il ou ne R o ef s R es r. v e2/ s- ae sa c ph e) r balance shest of (122.42) 16 | p E (r a Ae r v Bii ano su g is s c a pc ec ro eu qn ut ii tn yg s y he aa rr e for continuing operations 0 03 30 0 © ©. 11 17 )) ] ( (0 ..0 06 8) 0 044 19 8 ( (0 0. .0 04 4) ) ( (0 0. .0 08 8) )! | 17 | ( E (B Aa) )r nD Bii al n su g it s ce d p er equity share for discontinuing operations - - - - - - - - - - - - (B) Diluted 18 | E (Aa )m Bi an sg is c per equity sharefor discontinuing & continuing operations 0 0. .3 30 0 ( (0 0. .1 11 1) )] ] { {0 0. .0 06 6) )} | 0 0.1 19 9 ( 00 .. 00 44 )) ] ( {0 0. .0 08 8) )] ) (B) Diluted HINDUSTAN B+D51+B3:E34+B3:E36+D51+B+B3:E36 Plot No.31, Sagar Society, Road No.2, Banjara Hills, Hyderabad 500 034 Phone No. 23555161,Fax 40205171 STATEMENT OF ASSETS AND LIABILITIES Rs. In lakhs Asat PARTICULARS 30.09.2026 31.03.2026 ASSETS, 1[Non Current Assets (2) Fixed Assets 134 1.34] Tangible Assets 1.02 1.02] (6) Deferred Tax Asset 238.96 230.97] (c) Other Financial Assets 241.33 202.33] Total Non Current Assets 2|Current Assets 0| 9| (a) Stock in Trade 4151 5.30 (b) Trade Receivables 5.36) 13.03 (c) Cash and Cash Equivalents 57.84) 58.87) () Other Current Assets 31071 7721 Total Current Assets 352.04 319.54 TOTAL ASSETS EQUITY AND LIABILITIES 1|share Holders Funds 205.02 205.02] (a) Share Capital (102.67) (122.42) (b) Reserves and Surplus 102.34 2.60 Total of Share Holders Funds . 2|Non Current Liabilities 233.77 234.95 (a) Borrowings 233.77 234.95| Total Non Gurrent Liabilities 3|Current Liabilities ol of () Borrowings (b)Trade Payables 0 [} iT otal Outstanding dues of Micro Enterprises & Small Enterprises i Total Outstanding dues of Creditors other than Micro Enterprises ol 0.00) and small enterprises 13.80) 0.07] Other Current Liabilities . 244 1.92] Short Term Provisions 5.9 7.99) Sub Total -Current Liabilities 352.04 310.54 TOTAL EQUITY AND LAIBILITIES Notes +: The Un Audited Financial Results were taken on record by the Board of Directors in their meeting held on 31.10.2026 2 Previous Year figures have been regrouped wherever necessary. for Hindustan Bio Sciences Linited Place: Hyderabad J.V.R.Mohan Raju Date : 31.10.2026 Chairman & Managing Director { DIN:00060800 HINDUSTAN BIO SCIENCES LIMITED CIN: L26942TG1991PLC013564 Cash Flow Statement for the quarter and half year ended 30th September,2026 (Rs. In Lakhs) Particulars 30-09-2026 31-03-2026 A CASH FLOW FROM OPERATING ACTIVITIES Net Profit/(Loss) Before Tax 19.74 (7.93)| Adjustments for: . Gain on Sale of Assest Depreciation - 1.99 Operating Profit before Working Capital Changes 19.74 (5.93)| Movements in Working Capital Increase/(Decrease) in Trade Payables 13.72 0.01 Decrease/(Increase) in Provisions 0.22 0.62 Increase/(Decrease) in Borrowings - - Increase/(Decrease) in Trade Receivables (42.21) 38.90 Increase/(Decrease) in Inventories - - Decrease/(Increase) in Other financial assets 1.00 (1.00)) Decrease/(Increase) in Other current assets 1.04 (4.47) Cash generated from operations (6.49)) 28.13 Less: Income Tax Refund/paid - - Net Cash flow from Operating activities (6.49)) 28.13 B CASH FLOW FROM INVESTING ACTIVITIES - 41.06 Sale of Fixed Assets Purchase of Fixed Assets - (41.69) - (0.63)| Net Cash used in Investing activities C CASH FLOW FROM FINANCING ACTIVITIES Proceeds from/ [Showing first 8,000 characters — download PDF for full document]